Chemotherapy Compounding Drug Development 
STAT
OCTOBER 20, 2023
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.
European Pharmaceutical Review
DECEMBER 5, 2022
The PSMAfore results are the second positive set of data for Pluvicto in a Phase III trial, after the VISION clinical trial, where PSMA–positive mCRPC patients who received Pluvicto plus standard of care (SoC) after ARPI and taxane-based chemotherapy, showed statistically significant reduction in risk of death. The PSMAfore study.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 5, 2021
Understanding the mechanism of PPIs and developing methods to target aberrant ones has been a key strategy in drug development. The interface is highly hydrophobic, hence any compounds containing water would be repelled. The flat interface remains the primary challenge facing the development of PPI modulators.
Pharmaceutical Technology
FEBRUARY 24, 2023
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pharmaceutical Technology
AUGUST 12, 2022
By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. The standard first-line treatment for DLBCL is a chemotherapy regimen, alongside the monoclonal antibody rituximab. There are a total of 124 companies involved in CAR-T cell drug development for this indication.
Pharmaceutical Technology
FEBRUARY 13, 2023
This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Faslodex will be administered in the control arm of the Phase III study, allowing for direct comparison between the two ER degraders.
Pharmaceutical Technology
JULY 23, 2008
Despite the enormous growth being enjoyed by the global oncology market, potential cancer cures are left on laboratory shelves on a regular basis, according to Dr Victoria John, head of clinical partnerships at Cancer Research UK’s Drug Development Office. “Companies shelve research on a regular basis,” she says.
Expert insights. Personalized for you.
325 
Let's personalize your content